Eric K. Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared a poll on X:
“Polling Q6. Early-stage NSCLC.
If a patient with early-stage NSCLC achieves a pCR after neoadjuvant chemoimmunotherapy, is adjuvant immunotherapy still necessary?
- Yes, continue adjuvant IO – 24.6%
- No, pCR means stop – 57.9%
- Depends (comment below) – 17.5%.”
Narjust Florez, Associate Director of the Cancer Care Equity Program and Co-Director Young Lung Cancer Program at Dana-Farber Cancer Institute, shared this post, adding:
“Very controversial question and a gap in lung cancer – what do you think?”
More posts featuring Eric K. Singhi and Narjust Florez.